Home » Stocks » BHC

Bausch Health Companies, Inc. (BHC)

Stock Price: $29.70 USD 0.62 (2.13%)
Updated Jun 24, 2021 3:06 PM EDT - Market open
Market Cap 10.42B
Revenue (ttm) 8.04B
Net Income (ttm) -1.02B
Shares Out 358.40M
EPS (ttm) -2.86
PE Ratio n/a
Forward PE 6.62
Dividend n/a
Dividend Yield n/a
Trading Day June 24
Last Price $29.70
Previous Close $29.08
Change ($) 0.62
Change (%) 2.13%
Day's Open 29.41
Day's Range 29.24 - 29.78
Day's Volume 1,123,505
52-Week Range 14.86 - 34.80

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LAVAL, QC, June 22, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC)("Bausch Health," the "Company" or the "Offeror") today announced that it has extended the expiration date for its pr...

2 days ago - PRNewsWire

LAVAL, QC, June 21, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that D. Robert Hale has resigned from his role as an independent ...

3 days ago - PRNewsWire

LAVAL, QB and ST. PAUL, Minn., June 8, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that it...

2 weeks ago - PRNewsWire

LAVAL, Quebec, June 7, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health," the "Company" or the "Offeror") announced today the results to date of its pending cash tender ...

2 weeks ago - PRNewsWire

Larry Robbins (Trades, Portfolio)'s Glenview Capital Management has revealed an addition to its NewHold Investment Corp. ( NHIC , Financial) holding according to GuruFocus' Real-Time Picks, a Premium fe...

Other stocks mentioned: CI, DXC, MCK, NHIC, THC
2 weeks ago - GuruFocus

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

3 weeks ago - Zacks Investment Research

Looking for huge winners over the long run? Here are three top picks.

Other stocks mentioned: BMBL, BYND
3 weeks ago - The Motley Fool

PDUFA Action Date Is October 30 , 2021 LAVAL, QC and ALPHARETTA, Ga., June 2, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global ey...

Other stocks mentioned: CLSD
3 weeks ago - PRNewsWire

Organizations Also Launch Social Media Donation Program to Support Prevent Blindness and Broaden Patients' Access to Cataract Surgery and Care During June's Cataract Awareness Month LAVAL, QC and CHICAG...

3 weeks ago - PRNewsWire

Benjamin Graham is widely considered to be the father of value investing. He wrote the first widely-acclaimed book on finding undervalued stocks and using fundamental analysis to choose investments.

3 weeks ago - GuruFocus

Benjamin Graham is widely considered to be the father of value investing. He wrote the first widely-acclaimed book on finding undervalued stocks and using fundamental analysis to choose investments.

3 weeks ago - GuruFocus

LAVAL, Quebec, May 27, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by $100 million through the redemption of ...

4 weeks ago - PRNewsWire

LAVAL, QC, May 25, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that Joseph C. Papa, chairman and chief executive officer; Sam Eld...

4 weeks ago - PRNewsWire

LAVAL, QC, May 24, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has priced its previously announced offering of $1.6 billi...

4 weeks ago - PRNewsWire

LAVAL, Quebec, May 24, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health," the "Company" or the "Offeror") announced today that it has commenced a cash tender offer (the "...

1 month ago - PRNewsWire

LAVAL, Quebec, May 24, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has launched an offering of $1.6 billion aggregate pri...

1 month ago - PRNewsWire

TRULANCE® (plecanatide) ePoster Will be Honored as Poster of Distinction LAVAL, QC, May 17, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology b...

1 month ago - PRNewsWire

LAVAL, Quebec, May 6, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that the Company will participate in multiple upcoming investor...

1 month ago - PRNewsWire

Bausch (BHC) beats on earnings but misses on sales in the first quarter due to the ongoing pandemic.

1 month ago - Zacks Investment Research

Poorly managed companies may not be on everyone's radar, but they're top picks for activist investors looking to boost shareholder value.

Other stocks mentioned: ACIW, CUB, DANOY, DK, ELAN, FE, FWRD ...
1 month ago - Kiplinger

BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics appoints Brent Saunders, Robert Ruffolo, Ph.D., and Robin Steele to its Board of Directors

1 month ago - Business Wire

These two battered stocks have reignited investors' passion over the past year. Can their momentum last?

Other stocks mentioned: GME
1 month ago - The Motley Fool

The company's mixed Q1 results are partially to blame.

1 month ago - The Motley Fool

Bausch Health and Albertsons offer excellent bang for your buck.

Other stocks mentioned: ACI
1 month ago - The Motley Fool

Bausch (BHC) delivered earnings and revenue surprises of 10.64% and -2.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

LAVAL, Quebec, May 4, 2021 /PRNewswire/ --  First-Quarter 2021 Financial Results Revenues of $2.027 Billion GAAP Net Loss of $610 Million Adjusted EBITDA (non-GAAP) 1 of $852 Million GAAP Cash Generated...

1 month ago - PRNewsWire

LAVAL, Quebec, May 3, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by $100 million through the redemption of o...

1 month ago - PRNewsWire

Bausch Health Companies Inc (NYSE: BHC) said in August that it would spin off its eye-care unit and operate it as an independent, publicly traded company. As a standalone company, Bausch + Lomb could be...

1 month ago - Benzinga

One Podium Presentation and 11 Poster Presentations to be Featured LAVAL, QC, April 29, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX...

1 month ago - PRNewsWire

In recent years, one of the worst hedge fund trades was Bill Ackman (Trades, Portfolio)'s Valeant (today called Bausch Health Companies Inc. ( BHC , Financial)) debacle.

1 month ago - GuruFocus

LAVAL, Quebec, April 28, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced the election of the 13 directors nominated at its 2021 annua...

1 month ago - PRNewsWire

LAVAL, QC, April 27, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced the Company is providing a presentation on its business during t...

1 month ago - PRNewsWire

SOPHIA ANTIPOLIS, France, and LAVAL, Quebec, April 16, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), Bausch + Lomb, its leading global eye health ...

2 months ago - PRNewsWire

3 Generic Drug Stocks to Watch Amid COVID-Related Recovery

Other stocks mentioned: AMPH, RDY, TEVA
2 months ago - Zacks Investment Research

All Primary and Secondary Endpoints Were Achieved LAVAL, QC and HEIDELBERG, Germany, April 13, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (N...

2 months ago - PRNewsWire

Looking for outside-the-box investments in an overvalued market? Here are your best bets.

Other stocks mentioned: ACB, AMC
2 months ago - The Motley Fool

LAVAL, QC, April 9, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its first-quarter 2021 financial results on Tuesday, May 4, 2021. Bausch Health will ...

2 months ago - PRNewsWire

Proprietary Blend of Five Live Probiotic Strains Shown to Help Reduce Severity and Frequency of Common, Occasional GI Symptoms* Now Rolling out to Major U.S. Retailers LAVAL, QC, April 8, 2021 /PRNewswi...

2 months ago - PRNewsWire

New OVD Offers Exceptional Corneal Protection, Visibility During Ophthalmic Surgery LAVAL, QC, April 7, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companie...

2 months ago - PRNewsWire

LAVAL, Quebec, April 7, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by $100 million through the redemption of...

2 months ago - PRNewsWire

Larry Robbins ( Trades , Portfolio )'s firm has revealed a new buy into Longview Acquisition Corp. II (NYSE:LGV.U) according to GuruFocus' Real-Time Picks, a Premium feature.

Other stocks mentioned: CI, DXC, TAK, THC
2 months ago - GuruFocus

LAVAL, Quebec, March 31, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that it and certain of its affiliates have entered into a de...

2 months ago - PRNewsWire

After previously exiting a position in the fourth quarter of 2020, Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed a new 5.03% stake in Tricida Inc. (NASDAQ:TCDA) earlier this...

Other stocks mentioned: AZN, BIIB, BMY, LLY, MRK, TCDA
2 months ago - GuruFocus

Francis Chou (Trades, Portfolio)'s Chou Associates and Prem Watsa (Trades, Portfolio)'s Fairfax Financial both own a significant stake in Resolute Forest Products (NYSE:RFP).

Other stocks mentioned: RFP
2 months ago - GuruFocus

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

There are challenges to value creation in the proposed separation of Bausch Health Companies Inc's (NYSE: BHC) Bausch and Lomb (B&L) unit and RemainCo, which will be pharma-focused, according to BofA Se...

3 months ago - Benzinga

Larry Robbins ( Trades , Portfolio )'s firm has revealed a new buy into HighCape Capital Acquisition Corp. (NASDAQ:CAPA) according to GuruFocus' Real-Time Picks, a Premium feature.

Other stocks mentioned: CAPA, CI, DXC, TAK, THC
3 months ago - GuruFocus

Sam Eldessouky Will Succeed Paul S. Herendeen as Chief Financial Officer, Effective June 1, 2021 Herendeen Will Remain at Bausch Health as Advisor to the Chairman and CEO LAVAL, Quebec, March 11, 2021 /...

3 months ago - PRNewsWire

It depends on if you believe the troubled drugmaker can stage a comeback.

3 months ago - The Motley Fool

LAVAL, Quebec, March 9, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") has published a presentation that Joseph C. Papa, chairman and CEO, Sam Eldes...

3 months ago - PRNewsWire

About BHC

Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded an... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Stock Exchange
NYSE
Ticker Symbol
BHC
Full Company Profile

Financial Performance

In 2020, BHC's revenue was $8.03 billion, a decrease of -6.67% compared to the previous year's $8.60 billion. Losses were -$560.00 million, -68.68% less than in 2019.

Financial Statements

Analyst Forecasts

According to 19 analysts, the average rating for BHC stock is "Buy." The 12-month stock price forecast is 35.33, which is an increase of 18.96% from the latest price.

Price Target
$35.33
(18.96% upside)
Analyst Consensus: Buy